Skip to main content
Premium Trial:

Request an Annual Quote

AxCell to Conduct Pilot Study for Pluvita

NEW YORK, Dec. 11 - AxCell Biosciences said Tuesday it had agreed to run a pilot program for Pluvita to determine protein interactions based on signal transduction research.

Axcell said it would identify full-length peptides that bind to a compound Pluvita has earmarked for the research program. 

Financial and other terms of the agreement were not disclosed. 

The deal signals a furthering of the relationship between the two companies. Last month, Pluvita of Bethesda, Md., signed a three-year deal for access to AxCell ProChart database, which contains information on signal transduction pathways in the human proteome.

"AxCell's platform technology should help us to identify drugs that target pathways related to a specific disease while avoiding the pathways associated with unwanted side effects,” Gary Kurtzman, CEO of Pluvita, said in a statement.

Pluvita is developing drugs for cancer and reproductive diseases. 

AxCell Biosciences of Princeton, NJ, is a subsidiary of Cytogen.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.